BeOne Medicines today announced a $300 million expansion of its flagship clinical and commercial-stage manufacturing and research and development center at the Princeton West Innovation Campus in Hopewell, New Jersey. The company said the expansion brings its total U.S. manufacturing investment to more than $1 billion.
The expansion will increase BeOne's production capacity to manufacture its medicines and is expected to create approximately 120 new full-time jobs. It supports the continued advancement of BeOne's oncology pipeline of more than 35 clinical and commercial-stage assets.
With this expansion, BeOne's Princeton West Innovation Campus will become a fully integrated, multi-platform manufacturing site, combining existing biologics production with new small molecule drug product capabilities under one roof.
The expansion involves construction of a new three-story, 145,000-square-foot building adjacent to BeOne's existing Hopewell facilities, bringing the total campus footprint to approximately 545,000 square feet. The new building will house drug product manufacturing and packaging operations that strengthen BeOne's production and supply chain capabilities to support its growing hematology portfolio and pipeline, alongside quality control laboratories, office space, and capacity reserved for future growth. The expanded site will also provide additional flexibility to support strategic collaborations with partners and advance BeOne's global development superhighway.
This strategically advantaged model combines one of the industry’s largest oncology research teams with nearly 6,000 clinical development and manufacturing colleagues, helping reduce the cost and time required to develop new medicines for cancer patients around the world. The added capacity will support pipeline programs across multiple blood cancers, as well as breast, gynecologic, lung, liver, gastrointestinal, and other tumor types. These programs span multiple innovative modalities, including small molecules, biologics, targeted protein degraders, multispecific antibodies, and antibody drug conjugates.
